Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Nov 21, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational...

Nov 14, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare diseases....

Nov 14, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most...

Events & Presentations
Thursday, November 21, 2019
1:20pm - 1:55am GMT
Thursday, November 14, 2019
8:00am - 11:00am EST

Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information